menu
    • menu

    Company profile for Wren Therapeutics

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process. These advances make it possible to map, and selectively modulate, the complex and non-linear chemical kinetic networks associated with misfolding proteins and disease. . Wren is using its unique approach to develo...
    Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process. These advances make it possible to map, and selectively modulate, the complex and non-linear chemical kinetic networks associated with misfolding proteins and disease. . Wren is using its unique approach to develop a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases. It is s a spin-off company from the University of Cambridge

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Wren Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Cambridge, GB
    Telephone
    Telephone
    10054518
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Something in the water? 2 biotechs cast off old names
    Something in the water? 2 biotechs cast off old names

    01 May 2023

    // Ben Adams FIERCE PHARMA

    https://www.fiercepharma.com/marketing/something-water-two-biotechs-cast-old-names-they-shore-new-identities

    Ben Adams FIERCE PHARMA
    01 May 2023
    Share Share
    Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave
    Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave

    25 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wren-therapeutics-renamed-wavebreak-signifying-focus-on-stopping-the-wave-of-neurodegeneration-in-parkinsons-diseasealzheimers-disease-and-als-at-its-source-301806233.html

    PR NEWSWIRE
    25 Apr 2023
    Share Share
    Wren Presents Preclinical Data at AD/PD 2023 Demonstrating Potential of its First-in-Class, Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for the Treatment of Parkinson's Disease
    Wren Presents Preclinical Data at AD/PD 2023 Demonstrating Potential of its First-in-Class, Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for the Treatment of Parkinson's Disease

    29 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wren-presents-preclinical-data-at-adpd-2023-demonstrating-potential-of-its-first-in-class-small-molecule-inhibitors-of--synuclein-toxic-oligomers-for-the-treatment-of-parkinsons-disease-301784093.html

    PR NEWSWIRE
    29 Mar 2023
    Share Share
    Wren Appoints Bart Henderson as Chief Executive Officer
    Wren Appoints Bart Henderson as Chief Executive Officer

    04 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220304005036/en

    BUSINESSWIRE
    04 Mar 2022
    Share Share
    Wren Therapeutics raises £12.4m in latest financing round
    Wren Therapeutics raises £12.4m in latest financing round

    26 Jan 2021

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/wren_therapeutics_raises_12.4m_in_latest_financing_round_1361930

    Lucy Parsons PHARMATIMES
    26 Jan 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search